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Background: Vascular endothelial growth factor (VEGF) is a critical pro-angiogenic factor, found in a number of
cancers, and a target of therapy. It is typically assessed by immunohistochemistry (IHC) in clinical research. However,
IHC is not a quantitative assay and is rarely reproducible. We compared VEGF levels in colon cancer by IHC and a
quantitative immunoassay on proteins isolated from formalin fixed, paraffin embedded tissues.
Results: VEGF expression was studied by means of a well-based reverse phase protein array (RPPA) and
immunohistochemistry in 69 colon cancer cases, and compared with various clinicopathologic factors. Protein
lysates derived from formalin fixed, paraffin embedded tissue contained measurable immunoreactive VEGF
molecules. The VEGF expression level of well differentiated colon cancer was significantly higher than those
with moderately and poorly differentiated carcinomas by immunohistochemistry (P = 0.04) and well-based
RPPA (P = 0.04). VEGF quantification by well-based RPPA also demonstrated an association with nodal metastasis
status (P = 0.05). In addition, the normalized VEGF value by well-based RPPA correlated (r = 0.283, P = 0.018). Furthermore,
subgroup analysis by histologic type revealed that adenocarcinoma cases showed significant correlation (r = 0.315,
P = 0.031) between well-based RPPA and IHC.
Conclusions: The well-based RPPA method is a high throughput and sensitive approach, is an excellent tool for
quantification of marker proteins. Notably, this method may be helpful for more objective evaluation of protein
expression in cancer patients.
Keywords: Vascular endothelial growth factor, Formalin-fixed paraffin-embedded, Colon cancer,
Immunohistochemistry, Reverse-phase protein arrayBackground
The vascular endothelial growth factor (VEGF), one of
the key regulators of angiogenesis, is a major target for
anti-angiogenic therapy. VEGF overexpression has been as-
sociated with vessel invasion [1,2], tumor progression and
poor prognosis in several tumor entities, including colorec-
tal cancer [3,4]. It is reported that there is a correlation* Correspondence: genejock@helix.nih.gov
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unless otherwise stated.between VEGF expression and microvessel density [5,6];
therefore, the precise quantification of VEGF expression of
clinical specimens is an invaluable factor for understanding
clinical outcome, pathophysiological processes or thera-
peutic responses. In diagnostic pathology setting, tissue
samples are mainly preserved as formalin fixed, paraffin
embedded (FFPE) tissue blocks for histological examin-
ation. Currently, VEGF expressions of clinical FFPE tissue
specimens are routinely assessed by immunohistochemis-
try, however quantification is limited.
Immunochemistry has been used as an adjunct diagnos-
tic method as well as a validation tool of candidateLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 Characteristics of cases
Factor Characteristics No. of cases (%)
Gender Male 39 (56.5%)
Female 30 (43.5%)
Differentiation Well 3 (4.3%)
Moderately 31 (44.9%)
Poorly 35 (50.7%)
Histologic type Adenocarcinoma 46 (66.7%)
Mucinous carcinoma 23 (33.3%)




N classification N0 34 (50.0%)
N1 22 (32.4%)
N2 12 (17.6%)
Vascular invasion Absent 60 (87.0%)
Present 9 (13.0%)
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http://www.proteomesci.com/content/12/1/27biomarkers for a variety of cancers. Unfortunately, immu-
nohistochemistry is labor intensive and stained specimens
must be evaluated by a pathologist one at a time. In
addition, several difficult issues remained in evaluation of
immunohistochemistry, including the subjective of deter-
mination of intensity [7]. Furthermore, immunohistochem-
ical studies with manual scoring are not a quantitative
measurement but rather a qualitative assessment. Although
image analysis overcomes some of these issues, it lacks
normalization to account for differences in tissue handling
and processing [8,9]. In order to overcome these limita-
tions of immunohistochemistry, a number of proteomic
based technologies have been developed and evaluated in
clinical research fields. Although these techniques are gen-
erally superior in expression profiling and quantitation of
protein changes associated with disease states, each has
significant limitations including specimen handling [10].
Many of these methods require frozen tissues or native
proteins of starting material required, such limiting their
application to FFPE tissue application [11]. Recent ad-
vances in techniques for extracting proteins from FFPE tis-
sue sections have been facilitating tissue protein profiling
in the clinical proteomics, with varying degrees of success
[12,13]. We described a proteomic profiling method which
can is applicable to routine clinical FFPE tissue specimens.
It is based on combined technologies as a new protein ex-
traction method and a novel protein array platform. We
have demonstrated that the array is reliable and a stable
proteomic profiling platform for clinical research areas [14].
Here we show that protein expressional assessment by
this protein-profiling platform, coupled with protein ex-
traction, correlated with immunohistochemical meas-
urement; therefore, suggesting that it can be used as a
substitute method for conventional immunohistochem-
istry of FFPE tissue specimens. The new proteomic pro-
filing method reported here is, especially in secreted
proteins, a sensitive and specific method capable of effi-
ciently unraveling molecular profiles associated with
disease status or clinical outcome.
Results
Clinicopathologic characteristics of patients
The characteristics of the cases are summarized in Table 1.
The ages of the patients ranged from 26 to 89 years (mean,
68.6 years). Thirty-nine patients were men and 30 were
women. Six cases were T1 tumors, 9 T2, 43 T3, and 11 T4.
Twenty-two patients (32%) had nodal metastasis associated
with the primary tumor. Microscopic vascular invasion
was identified in 13% of patients (9 cases).
Immunoreactivity of protein extracted from FFPE
tissue specimens
Prior to application of the well-based reverse phase VEGF
quantitation, we examined protein quality to determinewhether the proteins extracted from archival FFPE human
colon specimens were of sufficient quality for well-based
reverse-phase protein array (RPPA). We extracted measur-
able immunoreactive proteins that demonstrated specific
signal of the predicted molecular weight by immunoblot-
ting analysis including VEGF and GAPDH, respectively
(Figure 1A). Having the immunoreactive proteins, we evalu-
ated whether a well-based RPPA is compatible for VEGF as-
sessment in clinical specimens. Internal control (GAPDH)
signals of clinical specimens were strongly correlated with
input amount of protein (R2= 0.9992). Subsequently, we are
also confirmed high sensitivity and linearity of using anti-
VEGF (R2 = 0.9597), with dynamic range from 0.03 μg to
1.0 μg (Additional file 1: Figure S1). As shown in Figure 1B,
relative VEGF signals in two different colon tissues were
measured and the ratio of VEGF to GAPDH was calcu-
lated. Although there is similar expression pattern between
well-based RPPA and immunoblotting, the expression level
of novel protein array has a better dynamic range than
immunoblotting.
VEGF immunohistochemical staining
To determine whether VEGF immunohistochemical ex-
pression is associated with clinicopathologic factors in
colon cancer, we assessed VEGF expression patterns by
semiquantitative analysis of immunohistochemical stain-
ing. Representative images of VEGF immunohistochemical
staining are illustrated in Figure 2. Results of VEGF immu-
nohistochemistry analysis are summarized in Table 2.
Mean histo-score of well differentiated colon cancer (20.0)
was significantly higher than those with moderately (10.9)













































Figure 1 VEGF expression profiling by well-based reverse
phase protein array and western blotting. We extracted total
proteins from 2 different colon FFPE tissue specimens. (A)Western
blotting shows different VEGF expression pattern. For reliable signal
quantitation on same blot, we reprobed the membrane with
anti-GAPDH antibodies. Quantative anlysis was performed using the
ImageQuant program. (B) VEGF and GAPDH expressional signals were
measured using well-based reverse phase protein array. Relative
expressional signal of VEGF was displayed as a ratio of VEGF to GAPDH.
Light bar and black bar represent results of western blotting and well-based
reverse phase protein array (RPPA), respectively. The bar graph shows
the average ± SD of two independent experiments.
A
Figure 2 Immunohistochemical analysis of VEGF expression in colon
expression are shown in normal colonic epithelia (A), adenocarcinoma (B),
adenocarcinoma and mucinous carcinoma were strong, while it was weak
Chung et al. Proteome Science 2014, 12:27 Page 3 of 8
http://www.proteomesci.com/content/12/1/27post-hoc Duncan, Figure 3A). However, there were no VEGF
expression differences when evaluated with respect to other
clinicopathologic factors.VEGF quantitation by well-based RPPA
To assess quantitative VEGF scoring, we performed the
well-based RPPA with human colon FFPE tissue speci-
mens. Results of VEGF quantitation by the well-based
RPPA are summarized in Table 2. Mean relative VEGF ex-
pression of well differentiated colon cancer (4.2) was sig-
nificantly higher than those with moderately (2.9) and
poorly differentiated (2.5) carcinomas (P = 0.04, ANOVA
post-hoc Duncan, Figure 3B). VEGF expression was higher
in female patients (3.1) than male patients (2.4, P = 0.03).
Cases with nodal status N0 (no lymph node metastasis)
showed a higher VEGF histo-score (3.1) than what pa-
tients with N1 (2.5) or N2 (2.3, P = 0.05) showed. There
was no VEGF expression difference based on other clini-
copathologic factors.
Correlation of VEGF quantitation based on input amount
of protein as well as histo-score of VEGF and novel VEGF
quantitation assay are summarized on Figure 4. There was
an excellent concordance of novel VEGF quantitation assay
between 500 ng and 1000 ng of input protein (P < 0.0001,
r = 0.79, Pearson’s correlation, Additional file 1: Figure S2).
In addition to the comparison of VEGF quantitation based
on input protein, we compared VEGF quantitation based
on a new assay with classic “semi-quantitation” of VEGF
immunohistochemical expression based on “Histo-score”.
Notably, unnormalized VEGF value by well-based RPPA
showed negative correlation (r= -0.350, P= 0.003, Figure 4A)
with immunohistochemical assessment, whereas the nor-
malized VEGF value based on GAPDH displayed statisti-
cally meaningful correlation (r= 0.283, P= 0.018, Figure 4B).
Furthermore, the adenocarcinoma type showed significantly
better correlation (r= 0.283, P= 0.018, Figure 4C) with im-
munohistochemical measurement than that of mucinous
adenocarcinoma type (r= -0.086, P = 0.703, Figure 4D) by
histological subgroup analysis.B C
tissues. Representative images (final magnification, × 40) of VEGF
mucinous adenocarcinoma (C). VEGF expression in tumor cells of
in normal colonic epithelia.
Table 2 Results of VEGF expression by immunohistochemical staining and well-based Reverse Phase Protein Array (RPPA)
Factor Characteristics Quantitation method
IHC Well-based RPPA
VEGFa P-value VEGFb P-value
Gender Male 8.7 0.07 2.4 0.03*
Female 12.5 3.1
Differentiation Well 20.0 0.04* 4.2 0.04*
Moderately 10.9 2.9
Poorly 9.1 2.5
Histologic type Adenocarcinoma 9.6 0.27 2.8 0.29
Mucinous carcinoma 11.9 2.5




N classification N0 12.4 0.16 3.1 0.05
N1 8.3 2.5
N2 8.3 2.3
Vascular invasion Absent 10.3 0.93 2.8 0.60
Present 10.0 2.6
aHisto-score was generated as the product of intensity times area.
bAfter normalization with GAPDH level, relative expressional signals were represented as a ratio.
*Significant at the level of P < 0.05.
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Angiogenesis is one of the hallmarks of cancer and has re-
cently become the target of therapeutic approaches in on-
cology. Vascular endothelial growth factor (VEGF) was
found to be associated with angiogenesis [15-17]. Due to
the VEGF expression’s correlation with metastasis and mor-
tality, anti-VEGF therapy shows promise to suppress tumor




















Figure 3 Relative expression rate of VEGF and its association with his
are calculated by immunohistochemistry (A) or well-based RPPA (B). Relati
GAPDH. Patients with well differentiated carcinomas had significantly highe
carcinomas. *P < 0.05, ANOVA post-hoc Duncan test.tumor angiogenesis, VEGF expression has been assessed
in tumor samples via detection of gene amplification or
mutation, qualitative RT-PCR, immunohistochemistry,
fluorescence in situ hybridization, and enzyme-linked
immunosorbent assays (ELISA). In clinical research
areas, ELISA and immunohistochemistry are commonly
employed as VEGF detection assays coupled with serum




























topathologic differentiation. Box plots of relative expression rates
ve expressional signal of VEGF was displayed as a ratio of VEGF to
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r = 0.283, p = 0.018
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r = -0.350, p = 0.003
Figure 4 Reliability of well-based RPPA and its correlation with immunohistochemistry. Scatter diagrams are presented by unnormalized
VEGF value vs. immunohistochemical VEGF score (A) and normalized VEGF value vs. IHC VEGF score (B). There was a statistically meaningful
correlation between expressional signals in the normalized VEGF value by well-based RPPA and immunohistochemical VEGF score (r = 0.283,
P = 0.018) whereas the unormalized VEGF signal was expressed negative correlation (r = -0.350, P = 0.003). By histologic subgroup analysis,
adenocarcinoma type (C) was only showed good correlation (r = 0.315, P = 0.031) with IHC assessment compare to that of mucinous adenocarcinoma
(r = -0.086, P = 0.703, D).
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burden and seem to associate with the overall survival of
patients with colorectal cancer [19,20]. Werther et al. [21]
showed a significant reduced overall survival in patients
with high levels of serum VEGF (>533 pg/ml) compared
with patients with serum values below this threshold. On
the other hand, studies using VEGF immunohistochemis-
try in FFPE tumor samples are less clear in terms of the
prognostic value of VEGF. Ferroni et al. [22] observed a
significant association between colorectal tumors with ad-
vanced stage and higher VEGF expression by immunohis-
tochemistry. In contrast, Lee et al. [4] and Khorana et al.
[23] showed VEGF expression was not associated with
survival. There are also conflicting reports between VEGF
expression and tumor differentiation. High levels of VEGF
expressions were significantly associated with poorly dif-
ferentiated tumors in colorectal carcinomas [24,25] and
soft tissue sarcomas [26]. In this study, however, VEGF ex-
pression was elevated in well differentiated tumors incomparison with poorly differentiated ones by immuno-
histochemistry (P = 0.04) and protein array (P = 0.04).
Similar findings were observed in other studies on colo-
rectal carcinoma [27,28] and esophageal squamous cell
carcinoma [29]. Overall the conflicting results of prior
studies may be explained by a lack of a standard immuno-
histochemical method, different standard of interpretation,
or differences in studies’ patient populations. Therefore,
these problematic environments of VEGF expression as-
sessment have caused some disparity in the reports of
VEGF expression as a prognostic marker. Immunohisto-
chemistry, although providing excellent localization, lacks
quantification without sophisticated instrumentation and
normalization in chromogenic applications.
As a validation study, we employed adenocarcinoma
and mucinous carcinoma histologic types for the well-
based RPPA assay. Although the adenocarcinoma sub-
group showed a good correlation between the well-based
RPPA and IHC, the mucinous carcinoma subgroup
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lularity of the samples, where the IHC, un-normalized is an
estimate based on a very small number of cells, while the
well-based RPPA is a normalized measure. Notably, there is
no correlation between tumor cellularity and VEGF expres-
sional signals by well-based RPPA (Spearman’s rho = 0.088,
P = 0.471) whereas the IHC values shown a statistical cor-
relation with the cellularity (Spearman’s rho = 0.700, P <
0.0001). To date, all immunohistochemical studies of VEGF
quantitation in colon cancer tissues are limited to tumor
areas and do not reflect the contribution of VEGF in adja-
cent tissue. Since VEGF is a secreted protein, its presence
not only in tumor cells but also in surrounding matrix
and cellular membranes has hampered its analysis by
immunohistochemistry [30,31]. Therefore, lysates of
whole sections would better represent the complex
VEGF expression pattern.
Formalin fixation results in protein cross-linking. More-
over, the protein quality of FFPE tissue is impacted by add-
itional pre-analytical variable factors including warm
ischemia, fixation time and tissue processing conditions
[32]. Although it is typical for extracted proteins from
FFPE tissue to show a "smear" on SDS-PAGE, the extent
of the smear is related to the specimen processing condi-
tions, with greater "smearing" indicates different degrad-
ation levels for each tissue sample. In this study, we used
GAPDH protein signal as an internal control to measure
the protein quality from each tissue sample. The GAPDH
protein has a relatively small molecular weight and is rela-
tively well-reserved in FFPE tissue [14]. In this context,
the VEGF signal was double normalized with total amount
of protein and the GAPDH signal. By employing the
normalization tool by GAPDH, our methodology has an
advantage that can evaluate VEGF value without the risk
of low reliability and poor validity in the current immuno-
histochemical VEGF assessment.
Conclusion
In conclusion, we revealed a better correlation and less
scattering using the novel protein array methodology in
tissue lysates of FFPE tissue. In addition, we showed the
new approach could be used for protein profiling analysis
in FFPE tissue, with quantification and normalization
tools. As a research tool, this method offers an additional
great tool for assessment of VEGF expression in transla-
tional medicine.
Methods
Patients and tumor samples
The study subjects were composed of 69 patients with sur-
gically resected colon cancer at RWTH Aachen University,
Aachen, Germany. Medical records were reviewed to ob-
tain data including age, gender of patients, cancer stage,
tumor differentiation, cell type, lymphovascular invasionand lymph node metastasis. Tissue samples were collected
from patients who had signed informed consent forms,
which was approved by the institutional review board of
the RWTH Aachen University Hospital. This study was
additionally approved by the Office of Human Subjects
Research at the NIH. Information on post-operative radi-
ation and/or chemotherapy, and outcome of patients were
not available.
Protein extractions from FFPE tissue sections
Protein extraction from two 10 μm FFPE tissue sections
was performed as previously described [14]. This method-
ology has the advantage of being compatible with archival
tissue and does not require deparaffinization. Briefly, sec-
tions were trimmed of excess wax and homogenized using
a Disposable Pellet Mixer in 200 μl protein extraction so-
lution [1x high pH Antigen retrieval buffer (pH 9.9)
(Dako, Carpinteria, CA), 1% NaN3, 1% SDS, 10% glycerol
and protease inhibitor (1 tablet/25 ml, Roche)], followed
by incubation for 15 min at 115°C within a pressure
cooker (Dako). After incubation, the tissue lysates were
centrifuged at 13,000 rpm for 30 min at 4°C. The superna-
tants were collected and stored at -20°C. Total protein
concentrations were measured with the BCA Protein
Assay kit (Pierce Biotechnology, Rockford, IL).
SDS-PAGE and western blotting
The protein extracted from FFPE tissue sections was re-
solved by 4-12% NuPAGE® Novex Bis-Tris polyacrylamide
gel, and electroblotted to nitrocellulose membrane using
iBlot™ Dry Blotting System (Invitrogen, Carlsbad, CA).
The membranes were blocked with 5% nonfat dry milk in
TBST (50 mM Tris, pH 7.5, 150 mM NaCl, 0.05% Tween-
20) for 1 h, washed, and subsequently incubated overnight
at 4°C in TBST with 5% BSA containing the following anti-
bodies; anti-VEGF (NeoMarkers, Fremont, CA, 1:50) and
anti-GAPDH (Calbiochem, Gibbstown, NJ, 1:5000). Specific
molecules were detected with horseradish peroxidase-
labeled anti-mouse antibodies (Chemicon International,
Temecula, CA) and enhanced with SuperSignal Chemilu-
minescence kit (Pierce Biotechnology). Signals were de-
tected on KODAK BIOMAX MR X-ray film (Kodak,
Rochester, NY). Quantative analysis of the western blotting
was performed using ImageQuant (Ver. 5.2, Molecular
Dynamics, Sunnyvale, CA).
VEGF quantitation by well-based reverse phase
protein array
VEGF expression signals from archival FFPE tissues were
measured as previously reported [14]. Briefly, five microli-
ters of protein extract from FFPE tissue specimen, at pre-
determined protein concentrations, were added to Meso
Scale Discovery (MSD, Gaithersburg, MD) Multi-Spot™
plates (MA2400 96 HB Plate). The plate was allowed to
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subsequently further incubated for 30 min at 37°C. The
antigen-coated plates were preincubated with 5% BSA in
PBST for 60 min at RT before primary antibody reactions.
Anti-VEGF (Neomarkers) and anti-GAPDH (Calbiochem)
were diluted 1:200 and 1:1000 with 5% BSA in PBST, and
then incubated overnight at 4°C. After washing with PBST,
the plates were incubated for 1 h with goat anti-mouse
SULFO-TAG™ antibodies at a dilution of 1:1000 (0.5 μg/ml)
with 5% nonfat milk in PBST. The plates were then aspi-
rated and washed three times with PBST. Finally, MSD-T
read buffer was added to the plates and they were read on
the MSD Sector Imager 2400 reader (Meso Scale Discov-
ery). BSA coated wells were included on each plate as a
control for non-specific binding effects. The values from
non-specific wells were subtracted from all standards sam-
ples to calculate actual value. Two independent experi-
ments were performed with triplicates.
Immunohistochemistry and scoring
Tissue sections were deparaffinized and rehydrated in xy-
lene and serial alcohol solutions, respectively. Endogenous
peroxidase was blocked by incubation in 3% H2O2 for
10 min. The antigen retrieval was performed in a steam
pressure cooker with prewarmed antigen retrieval buffer
pH 9 (Dako) at 95°C, for 20 min. To minimize non-specific
staining, sections were incubated with protein block
(Dako) for 15 min. Anti-VEGF antibody (Neomarkers,
1:50) were incubated for 60 min at RT. After secondary in-
cubation of Envision + kit/horseradish peroxidase (Dako),
substrate chromogen was added and specimens were
lightly counterstained with hematoxylin.
Protein expression for tumour cells was measured over
the full tissue specimen using the weighted histo-score
method [33]. The weighted histo-score grades staining in-
tensity as 0 (negative), 1+ (weak), 2+ (moderate), or 3+
(strong), then multiplication of percentage of tumor cells
within each category. Furthermore, three additional differ-
ent areas were scored by percentage and intensity: normal
colon epithelium, adjacent tissue and surrounding extra-
cellular matrix. Two independent pathologists (TB, SMH)
scored slides blindly and separately. For those cases with
discrepancy amongst pathologists, a decision was made
based on the consensus opinion.
Statistical analysis
Statistical analyses were performed using SPSS (version
19, Chicago, IL) and R (http://www.r-project.org). Com-
parison of means was performed using Student’s t-test,
Mann-Whitney, or one-way ANOVA tests. Linear regres-
sion analysis was performed to examine the relationship of
VEGF expression by immunohistochemical staining and
VEGF quantitation by well-based RPPA. A p-value less
than 0.05 was considered statistically significant.Additional file
Additional file 1: Figure S1. Protein expression profiling by well-based
RPPA. Figure S2. Reliability of well-based RPPA for VEGF assessment in
FFPE tissue lysates.
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